RecruitingPhase 2NCT07148947

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Anna Halpern, MD
Fred Hutch/University of Washington Cancer Consortium
Intervention
Pacritinib(drug)
Enrollment
27 target
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (1)

Collaborators

Swedish Orphan Biovitrum

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07148947 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm

← Back to all trials